MMV invites projects in the hits-to-lead stage for new families of molecules specifically addressing the significant priorities of the malaria eradication agenda, transmission blocking and prevention of P. vivax relapse. Proposals for chemical series with the potential for P. falciparum chemoprevention or blood stage efficacy as a result of long-half lives are encouraged, though the project should already have initial confirmation of in vivo oral blood stage activity. Early target validation falls outside of our mandate.
In the clinical arena, MMV invites proposals for the clinical development of new chemical entities. We have a strong pipeline of new molecules, and so welcome applications regarding capacity building to develop new sites for first-in-patient testing of these new molecules, including both blood stage, transmission blocking and vivax anti-relapse capabilities. Moreover, to celebrate the release of the Malaria Box, MMV will be providing up to ten Challenge Grants of USD 50,000. Proposals are expected to be at the concept stage (i.e. no prior experimental work is required) and to last no more than a year. These Challenge Grants will be prioritized based on scientific merit and according to the MMV strategy, and can constitute:
Screening: testing the MMV Malaria Box against malaria and other parasitological assays
Medicinal Chemistry: perform hit-to-lead or optimization chemistry on any anti-malarial series
Translational and Clinical Development: new methods to study or validate the inhibition of P.vivax relapses or the interruption of transmission
Deadline for submission of proposals is by 12 noon CET March 15th 2012.
For further information, visit the link.
